Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC — Stella

Recruiting

Back to Vorolanib trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Sun Yat-sen University Cancer Center, Guangzhou, Other (Non U.s.)

Key details

Phase

Safety & dosing

Sponsor

Sun Yat-sen University

Enrollment target

~21 participants

Started

July 2025

Primary completion

December 2026

Age range

18 Years – 85 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov